US Pharmaceutical Drug Delivery Market to Reach $1.24 Billion by 2031 as Biologics and Home-Based Care Reshape Therapeutic Delivery Models

US Pharmaceutical Drug Delivery Market by Route of Administration [Oral (Tablet, Capsule), Injectable, Topical (Cream, Transdermal, Suppositories), Ocular, Nasal, Transmucosal, Implantable], Application (Cancer, Diabetes), Care Setting - Forecast to 2031
The US Pharmaceutical Drug Delivery Market is poised for sustained growth, projected to increase from USD 0.94 billion in 2026 to USD 1.24 billion by 2031, registering a CAGR of 5.8% during the forecast period. As chronic disease prevalence intensifies and advanced biologics reshape therapeutic standards, drug delivery technologies are becoming a strategic priority for pharmaceutical manufacturers, healthcare providers, and investors alike.

Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=111487208 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=111487208&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

What is Driving Market Expansion-and Why Now?

One of the primary forces behind market expansion is the growing prevalence of chronic conditions such as cancer and diabetes. At the same time, the increasing adoption of biologics, biosimilars, peptide therapies, monoclonal antibodies, and mRNA-based treatments is redefining how therapies must be delivered. These complex molecules often require specialized systems to maintain stability, ensure bioavailability, and enhance patient adherence.

Modern drug delivery platforms-including lipid nanoparticles, autoinjectors, inhalers, transdermal patches, implantable systems, and controlled-release formulations-are essential to supporting advanced therapies such as cell and gene treatments. These systems are engineered to protect active ingredients during transit, deliver precise dosing, and improve therapeutic outcomes while minimizing systemic toxicity.

However, how sustainable is this innovation cycle? The market continues to face cost pressures. Drug-device combination products demand stringent quality control, specialized materials, and sophisticated engineering. Extended R&D timelines and increasingly rigorous regulatory approval processes-particularly around safety, usability, and device performance-add complexity and financial burden for manufacturers.

Injectable Segment to Lead Growth by Route of Administration

Based on route of administration, the injectable drug delivery segment is expected to grow at the highest CAGR during the forecast period.

Why injectables? Advanced biologics and large-molecule drugs typically exhibit poor oral bioavailability and are highly sensitive to gastrointestinal degradation, making parenteral administration essential. Innovations such as prefilled syringes, autoinjectors, depot injections, needle safety systems, and on-body wearable injectors are improving dosing accuracy, enhancing patient comfort, and reducing contamination risks.

As pharmaceutical pipelines increasingly prioritize biologics, injectable delivery systems are positioned to remain at the forefront of therapeutic expansion.

Cancer Segment Expected to Register Fastest Growth by Application

By application, the cancer segment is projected to witness the highest CAGR through 2031.

The rising incidence of cancer, coupled with broader adoption of targeted therapies and personalized medicine, is driving demand for advanced drug delivery mechanisms. Oncology treatments frequently involve monoclonal antibodies, antibody-drug conjugates, biologics, and chemotherapeutics that require controlled and precise administration.

Recent advancements-including implantable systems, long-acting depots, nanoparticle carriers, liposomal formulations, and on-body delivery platforms-enable localized, higher-concentration therapeutic delivery directly to tumor sites. This approach improves efficacy while reducing systemic side effects, making delivery innovation a critical competitive differentiator in oncology.

Home Care Settings Emerging as Fastest-Growing Care Model

Based on care setting, the home care segment is expected to register the highest CAGR during the forecast period.

Healthcare delivery in the US is shifting from hospital-centric models to outpatient and home-based care. Rising healthcare costs, patient preference for convenience, and expanded telemedicine infrastructure are accelerating this transition.

Self-administration technologies-including autoinjectors, wearable injectors, prefilled syringes, connected smart devices, and on-body delivery systems-are enabling real-time adherence monitoring and reducing the need for frequent clinical visits. For chronic conditions such as diabetes, cancer, autoimmune disorders, and cardiovascular diseases, home-based drug delivery provides both clinical continuity and cost efficiency.

Strategic Market Implications for Industry Leaders

For pharmaceutical executives, device manufacturers, and healthcare investors, the market's evolution raises critical questions:

*
How can organizations balance innovation with escalating development costs?

*
Where should capital be allocated-biologics, delivery platforms, or integrated combination products?

*
How will regulatory scrutiny influence go-to-market timelines?

The convergence of biologics growth, device innovation, and decentralized care models suggests that integrated drug-device strategies will define competitive advantage over the next decade.

Request For Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=111487208 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=111487208&utm_source=abnewswire.com&utm_medium=referral&utm_campaign=paidpr]

Key Market Participants

Prominent players operating in the US pharmaceutical drug delivery market include: Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), F. Hoffmann-La Roche (Switzerland), Becton, Dickinson and Company (US), Merck & Co., Inc. (US), Amgen, Inc. (US), AbbVie Inc. (US), Gilead Sciences, Inc. (US), Eli Lilly and Company (US), Bristol-Myers Squibb (US), Biogen (US), Baxter International (US), West Pharmaceutical Services (US), Catalent Pharma Solutions (US), and Novartis (Switzerland).

These companies are leveraging both organic innovation and strategic partnerships to expand delivery capabilities across oral, injectable, topical, ocular, nasal, transmucosal, and implantable platforms.

Conclusion

As the US pharmaceutical landscape transitions toward biologic-driven, patient-centric care models, drug delivery innovation is no longer a supporting function-it is a strategic growth engine. Stakeholders seeking competitive advantage must evaluate integrated delivery solutions, regulatory readiness, and scalable manufacturing capabilities to capture emerging opportunities through 2031.

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=us-pharmaceutical-drug-delivery-market-to-reach-124-billion-by-2031-as-biologics-and-homebased-care-reshape-therapeutic-delivery-models]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/us-pharmaceutical-drug-delivery-market-111487208.html

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.